** Drugmaker Biogen's shares BIIB.O fall 1.32% to $137.55 premarket
** Co forecasts 2025 adj. profit between $15.25/shr and $16.25/shr, below analyst est. of $16.34/shr, according to data compiled by LSEG
** Co reports Q4 profit of $3.44/shr, higher than analyst est. of $3.35/shr
** BIIB said it expects revenue to decline by a mid-single digit percentage in 2025 compared to 2024
** Co posts 2024 rev. of $9.68 bln, down 2% from a year earlier
** Stock fell ~42% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。